SC
XGN icon

Steven Cohen’s Exagen XGN Stock Holding History

Steven Cohen’s Portfolio XGN Stock Details XGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19,436
Closed -$58.3K – 4649
2026
Q1 		$58.3K Sell
19,436
-185,764
-91% -$718K ﹤0.01% 3652
2025
Q4 		$1.25M Buy
+205,200
New +$1.87M ﹤0.01% 2753
2025
Q3 		– Sell
-136,380
Closed -$952K – 2745
2025
Q2 		$952K Buy
+136,380
New +$829K ﹤0.01% 1577

Other funds holding XGN

WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $15.3B AUM 40.56% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
MBAM
Mink Brook Asset Management West Palm Beach, Florida $227M AUM 64.76% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

Steven Cohen's XGN Position: Q2 2026 in Review

Steven Cohen sold out of Exagen (XGN) in Q2 2026, closing a stake of 19,436 shares — an estimated $58.3K sold.

Steven Cohen first reported a position in XGN in Q2 2025 and held it in 3 quarters. The position peaked at $1.25M in Q4 2025. 57 funds tracked by Wall St. Rank hold XGN as of Q2 2026.

  • Steven Cohen reported no remaining Exagen position as of Q2 2026 after selling out during the quarter.
  • Steven Cohen sold 19,436 Exagen shares in Q2 2026, an estimated $58.3K.
  • Steven Cohen first reported a position in Exagen in Q2 2025 and held it in 3 quarters.
  • Steven Cohen's Exagen position peaked at $1.25M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held Exagen as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.